Properties (54)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
chemotherapy drug
|
| gptkbp:activeDuring |
paclitaxel
|
| gptkbp:availability |
prescription only
|
| gptkbp:chemicalFormula |
C47H51NO14
|
| gptkbp:clinicalTrials |
oncology
Phase III ABRAXANE for Breast Cancer Study ABRAXANE for Pancreatic Cancer Study ABRAXANE_for_Lung_Cancer_Study |
| gptkbp:contraindication |
anemia
allergic reactions infections thrombocytopenia severe liver impairment hypersensitivity to paclitaxel neutrophil count less than 1500/mm3 |
| gptkbp:dissolved |
water-soluble
|
| gptkbp:dosageForm |
lyophilized powder
|
| gptkbp:formulation |
albumin-bound
|
| gptkbp:hasPopulation |
adults
|
| https://www.w3.org/2000/01/rdf-schema#label |
Abraxane
|
| gptkbp:lastProduced |
gptkb:United_States
|
| gptkbp:launchSite |
IV infusion
|
| gptkbp:mandates |
non-small cell lung cancer
metastatic breast cancer metastatic pancreatic cancer |
| gptkbp:manufacturer |
gptkb:Celgene_Corporation
|
| gptkbp:marketedAs |
gptkb:Abraxane_for_Injectable_Suspension
|
| gptkbp:offers |
approximately $10,000 per month
|
| gptkbp:patentMaintenanceFee |
2005
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchFocus |
pharmacogenomics
combination therapies drug resistance |
| gptkbp:resources |
gptkb:NCCN_Guidelines_for_Breast_Cancer
gptkb:NCCN_Guidelines_for_Lung_Cancer NCCN_Guidelines_for_Pancreatic_Cancer |
| gptkbp:route |
intravenous
|
| gptkbp:sells |
gptkb:Abraxane
|
| gptkbp:shelfLife |
24 months
|
| gptkbp:sideEffect |
fatigue
nausea peripheral neuropathy hair loss neutropenia |
| gptkbp:storage |
room temperature
|
| gptkbp:targets |
microtubules
|
| gptkbp:triggerType |
inhibits cell division
|
| gptkbp:usedFor |
treatment of pancreatic cancer
treatment of breast cancer treatment of lung cancer |
| gptkbp:variant |
gptkb:carboplatin
gemcitabine |
| gptkbp:weight |
857.9 g/mol
|